

# BMJ Open Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study

Tomohiro Nishina <sup>1</sup>, Tomoko Fujita <sup>2</sup>, Naoto Yoshizuka <sup>2</sup>,  
Ko Sugibayashi <sup>3</sup>, Kosho Murayama <sup>2</sup>, Yasutoshi Kuboki <sup>4</sup>

**To cite:** Nishina T, Fujita T, Yoshizuka N, *et al.* Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study. *BMJ Open* 2022;12:e055718. doi:10.1136/bmjopen-2021-055718

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-055718>).

Received 30 July 2021  
Accepted 18 July 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Yasutoshi Kuboki;  
ykuboki@east.ncc.go.jp

## ABSTRACT

**Objectives** We assessed the safety, tolerability, pharmacokinetics, preliminary antitumour activity and pharmacodynamics of danvatirsen, an antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3), monotherapy and danvatirsen plus durvalumab, an antiprogrammed cell death ligand 1 monoclonal antibody, in patients with advanced solid malignancies.

**Design** Phase 1, open-label study with two cohorts.

**Setting** Two centres in Japan.

**Participants** Japanese individuals aged ≥20 years, with histologically confirmed solid malignancies, except for hepatocellular carcinoma, refractory to standard therapy.

**Interventions** In cohort 1, patients received danvatirsen monotherapy; in cohort 2, patients received danvatirsen plus durvalumab combination therapy.

**Primary and secondary outcome measures** The primary endpoint was safety and tolerability based on adverse events (AEs). Secondary endpoints were pharmacokinetics, immunogenicity, antitumour activity and pharmacodynamics.

**Results** Eleven patients were assigned to treatment and included in the analysis. Danvatirsen dose reductions were only required in cohort 2 for hepatic function abnormal (alanine aminotransferase (ALT)/ aspartate aminotransferase (AST)/gamma-glutamyl transferase (γGT) increased), neutrophil count decreased and platelet count decreased. One patient experienced grade 3 ALT/AST increased and new appearance of eosinophilia as a dose-limiting toxicity. AEs were reported in 90.9% (10/11) patients. Commonly reported AEs causally related to the danvatirsen were platelet count decreased (60% (3/5)) and ALT/AST/γGT increased (50% (3/6)) in cohorts 1 and 2, respectively; none was causally related to durvalumab. One serious AE occurred in cohort 1 (pancreatitis; unrelated to study treatment). One case of ALT/AST/γGT increased occurred in cohort 2, leading to discontinuation. No AEs led to death. Danvatirsen did not accumulate in

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This study is the first to report safety and preliminary efficacy data of combination danvatirsen/durvalumab therapy in Japanese patients.
- ⇒ Based on previous phase 1 study results in Asians, we excluded patients with hepatocellular carcinoma as we hypothesised that by doing so, we would avoid possible confounding factors and facilitate the detection of drug-related hepatotoxicity.
- ⇒ The sample size was small, which limited the interpretation of the antitumour activity and immunogenicity results.

plasma after multiple dosing. In cohort 2, three patients had disease control at 12 weeks and one had unconfirmed partial response. STAT3 expression tended to decrease regardless of monotherapy or combination therapy.

**Conclusions** Danvatirsen was well tolerated by Japanese patients with advanced solid tumours as monotherapy and combined with durvalumab. No new safety signals arose.

**Trial registration number** NCT03394144; ClinicalTrials.gov.

## INTRODUCTION

Signal transducer and activator of transcription 3 (STAT3) signalling is considered a driver of cancer development and progression via the transcriptional expression of target genes involved in cell cycle progression and the regulation of apoptosis.<sup>1 2</sup> STAT3 exerts pleiotropic actions in tumorigenesis and regulation of immune responses against cancer. It regulates the expression of many genes critically involved in the survival of tumour cells and also plays a role in the

function of non-tumour cells of the tumour microenvironment involved in immune evasion, angiogenesis and metastasis.<sup>1</sup> Although many attempts have been made to target STAT3, either by direct inhibition with small-molecule inhibitors<sup>3</sup> or pathway inhibition,<sup>4,5</sup> STAT3 has proven difficult to target.<sup>6</sup>

Danvatirsén (AZD9150) is a potent, 16-nucleotide, generation 2.5 antisense oligonucleotide that selectively targets STAT3 by downregulating STAT3 RNA in various cell types.<sup>7</sup> Danvatirsén enhances antigen-presenting cell function and regulates tumour cell proliferation.<sup>8</sup> Several clinical trials have provided early clinical evidence of the antitumour activity and tolerability of danvatirsén among patients with heavily pretreated lymphoma and lung cancer.<sup>9,10</sup> In a recent phase 1/1b study of danvatirsén monotherapy in Asian patients with hepatocellular carcinoma (HCC), danvatirsén was administered in a dose-escalation scheme starting at 1 mg/kg. Hepatic toxicity (elevation of hepatic transaminases) was the dose-limiting toxicity (DLT), and the maximum tolerated dose (MTD) was 2 mg/kg (unpublished data). DLTs were mainly attributed to the HCC-related hepatic compromise in these patients. Baseline hepatic dysfunction possibly made it difficult to consider the relationship between the observed hepatotoxicity and the safety and tolerability of danvatirsén. No significant differences in danvatirsén pharmacokinetics (PK) were observed between these patients and non-Asian patients in previous studies (unpublished data).

Due to the aggressive nature of malignancies, the aim of danvatirsén treatment is to downregulate phosphorylated STAT3 in tumours relatively quickly. Therefore, an initial loading dose was administered to ensure sufficient tissue accumulation of danvatirsén. Danvatirsén monotherapy at a 3 mg/kg ideal body weight (IBW)-based dose (corresponding to fixed dosing at 200 mg of the starting dose<sup>11</sup>) was tolerable in D5660C00004 (NCT02499328, unpublished data) and ISIS 481464-CS1 trials<sup>10</sup> investigating the safety and tolerability for non-Japanese patients with solid tumours and haematological malignancies. The impact of the IBW-based dose (3 mg/kg) versus fixed dose (200 mg) was evaluated by comparing simulated steady-state parameters using a population PK model. Simulation results demonstrated that IBW-based and fixed dosing regimens yielded similar median steady-state parameters. Therefore, danvatirsén 200 mg weekly is supported by previous trial experience and clinical PK data, except for patients with HCC.

Durvalumab is a fully human monoclonal antibody that inhibits programmed cell death ligand 1 (PD-L1). By binding to the receptors PD-1 and CD80, durvalumab can enhance T-cell recognition and responses against cancer cells.<sup>12</sup> Durvalumab is approved globally for the treatment of locally advanced non-small cell lung cancer following chemoradiation based on data from the PACIFIC trial,<sup>13</sup> and for use in combination with etoposide plus carboplatin or cisplatin as a first-line treatment for extensive-stage small-cell lung cancer based on data

from the CASPIAN trial.<sup>14</sup> In addition to these indications, durvalumab has shown clinical antitumour activity in other solid tumours,<sup>13</sup> including breast cancer,<sup>15</sup> and it is currently under extensive study for a broad range of solid tumours and haematological malignancies.<sup>12</sup>


The goal of using both danvatirsén and durvalumab as a complementary antitumour strategy is to impede immune-escape mechanisms in the tumour bed (danvatirsén) while promoting T-cell responses (durvalumab).<sup>9,16</sup> Phase 1b/2 and phase 2 studies for patients with advanced solid malignancies and recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) evaluated the antitumour activity of durvalumab plus danvatirsén may compared with durvalumab monotherapy.<sup>17,18</sup> The phase 1b/2 study reported an objective response rate (ORR) of 26% and the duration of response (DoR) was not reached,<sup>17</sup> whereas the phase 2 study reported an ORR of 16.2% and a DoR of 10.3<sup>18</sup>; both studies were small and had a DoR that was not interpretable or short. Of note, differences in the sample size, patient characteristics and study characteristics preclude direct comparison between studies. To date, the combination of danvatirsén with durvalumab (or any other prior anti-PD-1 and/or PD-L1 therapy) had not been studied in Japanese patients. This study aimed to assess the safety, tolerability, PK, preliminary antitumour activity and pharmacodynamics of danvatirsén monotherapy and danvatirsén in combination with durvalumab in Japanese patients with advanced solid malignancies.

## MATERIALS AND METHODS

### Study design

This was a phase 1, open-label study conducted between 30 January 2018 and 12 April 2019 at two centres in Japan. **Figure 1** shows the study design. In this study, we applied a 3+3 two-cohort dose-escalation scheme in which three to six evaluable patients were enrolled in cohort 1 and six were required for cohort 2. Cohort 1 comprised patients who received danvatirsén monotherapy, and cohort 2 comprised patients who received danvatirsén plus durvalumab combination therapy. A Safety Review Committee (SRC) evaluated the safety and tolerability of danvatirsén monotherapy or in combination with durvalumab during the study. The SRC decided whether to expand cohort 1, proceed to cohort 2 or if it was appropriate to stop study enrollment. The study included a lead-in phase of 7 days, in which loading doses of danvatirsén 200 mg were administered on days -7, -5 and -3. The DLT period consisted of the lead-in phase and cycle 1.

The Institutional Review Board approved the study protocol and related study documents. This study was performed according to the ethical principles stated in the Declaration of Helsinki, which are consistent with the International Council for Harmonisation/Good Clinical Practice, applicable regulatory requirements and the sponsor's policy on bioethics. At enrollment, all patients



**Figure 1** (A) Study design. (B) Dosing schedule. <sup>a</sup>Loading doses on days -7, -5, -3 of cycle 1 day 1. DLT, dose-limiting toxicity; q4w, every 4 weeks.

provided written informed consent to participate in the study. The study was registered at ClinicalTrials.gov.

### Treatment

Danvatirsen (cohorts 1 and 2) was administered via weekly 200 mg 1-hour infusions (day 1) in 4-week cycles after the initial 7-day lead-in phase. Durvalumab (cohort 2 only) 1500 mg was infused every 4 weeks after the administration of danvatirsen.

Regarding dose modification criteria for danvatirsen, if a patient experienced a clinically significant and/or unacceptable toxicity (including a DLT related to danvatirsen during the assessment period), drug administration was interrupted or the dose was reduced, and supportive therapy was administered as required. A recovery period of 21 days was allowed given the long half-life of danvatirsen in tissue. If the toxicity resolved or reverted to a lower Common Terminology Criteria for Adverse Events (CTCAE) grade within 21 days of onset

and the patient showed clinical benefit, study treatment could be restarted using the following dose modification criteria. For CTCAE grade 3 adverse events (AEs), if the AE reverted to grade 2 within 21 days, the dose level was reduced to 200 mg every 2 weeks. If a second interruption was needed, the dose level was decreased to 150 mg every 2 weeks. If patients started treatment with an abnormal baseline laboratory value, treatment could restart once the laboratory value returned to pretreatment levels. For grade 4 AEs, if the AE reverted to grade 2 within 21 days, the dose level was reduced to 150 mg every 2 weeks. If a second grade 4 AE occurred, or grade 3/4 AEs persisted longer than 21 days, the treatment was permanently discontinued, and the patient was followed up for safety. A maximum of two dose reductions was allowed for an individual patient. If the second dose reduction was not tolerated, study treatment was permanently discontinued, and the patient was followed up for safety. For durvalumab, dose modification was not allowed. Durvalumab administration was scheduled on day 1 of each 4-week cycle.

All medications (including study treatments) were recorded in electronic case report forms. Other medications necessary for the patients' safety and well-being were given at the discretion of the investigator. Patients could continue to receive the study treatment as long as they continued to show clinical benefit (as judged by the investigator) unless the patient had confirmed progressive disease, clinical deterioration and/or no further benefit from treatment, experienced unacceptable toxicity or discontinued for any other reason.

### Patients

Eligible participants were male or female Japanese patients, aged  $\geq 20$  years, with histologically confirmed solid malignancies (except for HCC) that were refractory to standard therapy or for which no standard of care regimen existed, had a body weight  $>30$  kg, Eastern Cooperative Oncology Group performance status score of 0 or 1, measurable disease, life expectancy  $>12$  weeks, adequate organ and bone marrow function, were women or men willing to use effective contraception before study entry and 20 weeks after study end, and women with child-bearing potential who had a negative pregnancy test.

The main exclusion criteria were untreated/unstable central nervous system involvement; any concurrent chemotherapy, radiotherapy, immunotherapy, or biologic, or hormonal therapy for cancer; toxicity related to prior treatment, except for alopecia and anorexia; immune-mediated AEs while receiving prior immunotherapy; immune disease that required systemic treatment for the past 2 years; inflammatory bowel disease; primary immunodeficiency; cardiovascular disease; severe systemic diseases or other severe or uncontrolled comorbidities; ascites or pleural effusion; other malignancies; bowel obstruction; active infections or any other condition that, in the opinion of the investigator, could interfere with patient safety or study evaluations.



### Primary endpoints: safety and tolerability

Safety was assessed according to AEs, serious AEs (SAEs), laboratory findings, vital signs and ECG data. Deaths, AEs leading to discontinuation of study treatment, other significant AEs and AEs of special interest were also evaluated. AEs were classified by the Medical Dictionary for Regulatory Activities V.22.0, system organ class (SOC), preferred term (PT) and CTCAE grade.

Tolerability was assessed based on DLTs, which were generally defined as drug-related AEs occurring from the initiation of danvatirsén until the end of cycle 1 and assessed as grade  $\geq 3$  according to the National Cancer Institute CTCAE. Exceptions are listed in online supplemental information.

### Secondary endpoints

#### Pharmacokinetics

The measures assessed were the concentration of danvatirsén and non-compartmental pharmacokinetic parameters, such as area under the curve, maximum plasma concentration and concentration at the end of a dosing interval. The same evaluations were done for the danvatirsén plus durvalumab combination therapy. The PK parameters were evaluated following the initial dose (day -7 of the lead-in phase) and following the repeated doses (day 1 of cycle 2). In the loading period, plasma concentrations were not determined after the second and third dose on days -5 and -3, respectively.

#### Immunogenicity

Immunogenicity was assessed based on the number and percentage of patients who developed detectable antidanvatirsén antibodies and antidurvalumab antibodies. Venous blood samples were collected predose on day 1 of cycle 1, cycle 2 and subsequent even-numbered cycles. Samples were evaluated for the presence of antidanvatirsén using a quantitative ELISA method and for antidurvalumab antibodies using a validated bridging immunoassay (Discovery SECTOR Imager equipped with Discovery Workbench 2006 MSD V.4.0; Meso Scale, Rockville, Maryland).

#### Antitumour activity

Antitumour activity was assessed based on the ORR, disease control rate and DoR. Tumour responses were evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1,<sup>19</sup> modified to account for unique responses to immunotherapy that may occur after progressive disease.<sup>20</sup> Tumour assessments were performed at screening, on cycle 1 day 1, every 6 weeks until week 12, and then every 8 weeks until the end of treatment visit.

#### Pharmacodynamics

Pharmacodynamic response was assessed by STAT3 RNA knockdown in blood. Blood samples (2.5 mL) for the evaluation of STAT3 RNA knockdown (danvatirsén) were collected from patients at screening, day -7 of the lead-in phase, day 1 and day 8 of cycle 1, day 1 of all subsequent

cycles, and at the end of treatment visit. RNA expression of STAT3 was measured using the nanoString nCounter system (NanoString Technologies, Seattle, Washington).

### Patient and public involvement statement

Neither the patients nor the public were involved in the design, conduct, reporting or dissemination plans of this research.

### Statistical analysis

Approximately 12 patients were planned for enrollment: three to six evaluable Japanese patients with advanced solid malignancies were required for cohort 1, and six evaluable patients were required for cohort 2. The total number of patients depended on the available data in each cohort and the decision of the SRC.


The safety analysis set included all patients who received at least one dose of danvatirsén or durvalumab. The efficacy analysis set included all patients with unidimensional measurable disease at baseline as per the RECIST V.1.1 criteria who received at least one dose of study treatment. The PK analysis set included all treated patients with reportable danvatirsén or durvalumab plasma concentrations and no important AEs or protocol deviations that could have impacted PK. The pharmacodynamic analysis set included all patients who provided biological samples for pharmacodynamic research.

No inferential testing was performed on safety data. Safety data were summarised using descriptive statistics. Summary statistics of mean, arithmetic mean (PK), median, SD, minimum, maximum and number of observations were used. Pharmacokinetic, immunogenicity and pharmacodynamic variables were analysed for all patients with available data; missing data were not imputed or carried forward. For the antitumour activity evaluation, if the target lesion measurements were missing, the response was classified as not evaluable. The statistical software used for the analysis was SAS V.9.4 or higher (SAS Institute, Cary, North Carolina). Biostatistics Group, AstraZeneca conducted statistical analysis.

## RESULTS

### Patient disposition and characteristics

Of the 12 patients enrolled, 11 (cohort 1, five patients; cohort 2, six patients) were assigned to receive the study treatment (figure 2). One patient was not assigned to receive the study treatment because of screening failure. Study treatment was discontinued due to disease progression for five (100%) patients in cohort 1 and five (83.3%) patients in cohort 2. In cohort 2, one (16.7%) patient discontinued study treatment due to a grade 3 AE of hepatic function abnormal (alanine aminotransferase (ALT)/aspartate aminotransferase (AST)). Five patients in cohort 1 and six patients in cohort 2 were included in the safety, PK, immunogenicity, antitumour activity and pharmacodynamics analysis sets.



**Figure 2** Patient disposition.

Regarding the demographic and clinical characteristics at baseline (table 1), more male than female patients were enrolled in both cohorts. Patients had a median age of 68 years (41–77), a median body weight of 64.3 kg (44.5–91.6) and a median body mass index of 25.7 kg/m<sup>2</sup> in cohort 1 and 22.3 kg/m<sup>2</sup> in cohort 2. The most commonly reported tumour locations were the colon (two (40%) patients in cohort 1; one (16.7%) patient in cohort 2) and oesophagus (two (40%) patients in cohort 1; three (50%) patients in cohort 2). All oesophageal tumours were squamous cell carcinomas. Body weight, age and body mass index were comparable between cohorts, but disease characteristics were less evenly distributed between cohorts regarding tumour grades.

## Study endpoints

### Safety and tolerability

There were no dose reductions for danvatirsén in cohort 1. In cohort 2, dose reductions of danvatirsén were reported for three (50%) patients: one patient (16.7%) with grade 3 hepatic function abnormal (ALT/AST/gamma-glutamyl transferase (γGT) increased), one patient (16.7%) with grade 3 neutrophil count decreased, and one patient (16.7%) with grade 3 platelet count decreased. The relative dose intensity (RDI) of danvatirsén in cohort 1 was 100%, and that in cohort 2 was 91%. As there were no dose interruptions, reductions or modifications for durvalumab in cohort 2, the RDI of durvalumab was 100%. Regarding tolerability, a single DLT was reported for one (16.7%) patient in cohort 2 with a grade 3 hepatic function abnormal event (ALT/AST/γGT increased) and new appearance of eosinophilia (>5%), indicating danvatirsén monotherapy with fixed dosing and its combination with durvalumab were tolerable in this Japanese population.

A total of 18 AEs were reported for four (80%) patients in cohort 1, and 28 AEs were reported for six (100%)

patients in cohort 2 (online supplemental table 1). Six AEs considered to be causally related to study treatment were reported for three (60%) patients in cohort 1, and 19 AEs considered causally related to study treatment were reported for six (100%) patients in cohort 2. At least one AE of CTCAE grade ≥3 was reported for three (60%) patients in cohort 1 and six (100%) patients in cohort 2.

One SAE of pancreatitis, considered unrelated to study treatment, was reported for one (20%) patient in cohort 1, and one grade 3 AE (hepatic function abnormal (ALT/AST/γGT increased)) leading to discontinuation was reported for one (16.7%) patient in cohort 2. No AEs leading to death or other significant AEs were reported. One patient died in each cohort, and the cause of death in both cases was disease progression.

By SOC, the most commonly reported AEs in cohort 1 were investigations (four (80%) patients) and in cohort 2, investigations and general disorders and administration site conditions (four (66.7%) patients, each). By PT, the most commonly reported AE was platelet count decreased for three (60%) patients in cohort 1 and hepatic function abnormal (ALT/AST/γGT increased) for three (50%) patients in cohort 2.

Table 2 summarises the most common grade ≥3 AEs. The most common SOC (CTCAE grade ≥3) was metabolism and nutrition disorders for cohort 1 and investigations for cohort 2. More patients in cohort 2 reported CTCAE grade ≥3 AEs than in cohort 1. No significant safety abnormalities were reported concerning grade 3 laboratory shifts, ECGs and vital signs.

### Pharmacokinetics

After a single intravenous infusion at 200 mg over 1 hour on day –7 of the lead-in phase, plasma concentrations of danvatirsén in cohort 1 and cohort 2 declined in a bi-phasic fashion, with a fast distribution phase and a slow elimination phase (online supplemental figure 1A). The geometric mean plasma concentration of danvatirsén (cohort 1) declined rapidly after the end of the infusion, similarly to the single-dose pharmacokinetic profile determined in the lead-in phase on day –7 (online supplemental figure 1B), suggesting no accumulation of danvatirsén in plasma after administration of multiple doses. The geometric mean plasma concentrations of danvatirsén were slightly lower for cycle 2, day 1 than those of the lead-in period (online supplemental figure 1C). We compared the pharmacokinetic parameters of danvatirsén between cohorts 1 and 2 (online supplemental table 2). Individual values in cohort 1 were within the range of corresponding values in cohort 2, suggesting no remarkable drug interaction between danvatirsén and durvalumab.

### Immunogenicity

Out of 23 samples, four were identified as potentially positive at the screening assay, two of which were confirmed positive for antibodies to danvatirsén. Of note, the two positive samples were from the same

**Table 1** Baseline patient characteristics and demographics

	Danvatirsen monotherapy (cohort 1) N=5	Danvatirsen+durvalumab (cohort 2) N=6	Total N=11
Sex			
Male	4 (80.0)	4 (66.7)	8 (72.7)
Age, median (range), years	68.0 (41–73)	67.0 (63–77)	68.0 (41–77)
Weight, median (range), kg	64.8 (61.4–91.6)	63.9 (44.5–71.1)	64.3 (44.5–91.6)
Body mass index, median (range), kg/m <sup>2</sup>	25.7 (21.9–34.7)	22.3 (19.5–28.1)	22.7 (19.5–34.7)
ECOG PS			
0	3 (60.0)	5 (83.3)	8 (72.7)
1	2 (40.0)	1 (16.7)	3 (27.3)
Primary tumour location			
Oesophagus	2 (40.0)	3 (50.0)	5 (45.3)
Colon	2 (40.0)	1 (16.7)	3 (27.3)
Rectum	1 (20.0)	0	1 (9.1)
Uterine corpus	0	1 (16.7)	1 (9.1)
Unknown	0	1 (16.7)	1 (9.1)
Tumour grade			
Well-differentiated	1 (20.0)	1 (16.7)	2 (18.2)
Moderately differentiated	3 (60.0)	2 (33.3)	5 (45.5)
Poorly differentiated	0	1 (16.7)	1 (9.1)
Not assessable	0	2 (33.3)	2 (18.2)
High grade	1 (20.0)	0	1 (9.1)
Histology type			
Squamous cell carcinoma of the oesophagus	2 (40.0)	3 (50.0)	5 (45.5)
Tubular adenocarcinoma of the colon	2 (40.0)	1 (16.7)	3 (27.3)
Adenocarcinoma*	1 (20.0)	1 (16.7)	2 (18.2)
Endometrioid adenocarcinoma	0	1 (16.7)	1 (9.1)
Overall disease classification†			
Metastatic	5 (100.0)	6 (100.0)	11 (100.0)
Locally advanced	1 (20.0)	1 (16.7)	2 (18.2)
No evidence of disease	0	0	0
Missing	0	0	0

Data are n (%).

\*One case of adenocarcinoma of the rectum in cohort 1 and one case of adenocarcinoma located in 'other' in cohort 2.

†Classifications were not mutually exclusive.

ECOG PS, Eastern Cooperative Oncology Group Performance Status.

patient in cohort 2. There was an eightfold titre increase from day 1 of cycle 4 (titre: 100) to day 1 of cycle 6 (titre: 800). This patient did not have any SAEs but did present a grade 3 AE of platelet count decreased. Predose plasma concentrations of danvatirsen in this patient were 37.7, 46.2, 41.1 and 80.4 ng/mL on day 1 of cycles 1, 2, 3 and 5, respectively. The best objective response of this patient was stable disease for ≥6 weeks. All 17 samples assessed for antibodies to durvalumab were negative.

### Antitumour activity

Efficacy parameters are summarised in online supplemental table 3. No confirmed complete response (CR) or partial response (PR) was recorded during the study. No

patient achieved an objective response, and three (50%) patients in cohort 2 had disease control at 12 weeks.

In cohort 2, PR was observed in one patient and stable disease for ≥6 weeks was reported for five (83.3%) patients. Progression was reported for five (100%) patients in cohort 1. Of these, four (80%) patients had RECIST progression, and one (20%) patient died of disease progression.

A patient in cohort 2 presented with a 49.1% reduction from baseline in target lesion size (hepatic metastasis), which was assessed as unconfirmed PR (figure 3). This patient had oesophageal carcinoma and metastatic lesions to hepatic lymph and gall bladder lymph nodes. The patient died during

**Table 2** Incidence of grade  $\geq 3$  AEs

System organ class MedDRA preferred term	Danvatirsen monotherapy (cohort 1) N=5	Danvatirsen+durvalumab (cohort 2) N=6
Patients with any AE	3 (60.0)	6 (100.0)
Metabolism and nutrition disorders	2 (40.0)	1 (16.7)
Hypermagnesaemia	1 (20.0)	0
Hypertriglyceridaemia	0	1 (16.7)
Hypokalaemia	1 (20.0)	0
Gastrointestinal disorders	1 (20.0)	0
Pancreatitis	1 (20.0)	0
Hepatobiliary disorders	0	2 (33.3)
Hepatic function abnormal (ALT/AST/ $\gamma$ GT increased)	0	2 (33.3)
Investigations	1 (20.0)	3 (50.0)
Neutrophil count decreased	0	2 (33.3)
ALT increased	1 (20.0)	0
AST increased	1 (20.0)	0
Blood bilirubin increased	1 (20.0)	0
$\gamma$ GT increased	1 (20.0)	1 (16.7)
Platelet count decreased	0	1 (16.7)

Data are n (%).  
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase;  $\gamma$ GT, gamma-glutamyl transferase.

the study follow-up period from disease progression (liver and distant lymph nodes). In cohort 2 (n=5), the median per cent change from baseline at 12 weeks in target lesion size was 17.59 (min: -40.4%, max: 90.0%).

### Pharmacodynamics


The mean (SD) for percent change from baseline of STAT3 at day 1 of cycle 2, when steady-state drug concentrations were achieved, was -25.14 (10.6) for cohort 1 (only two of five patients in cohort 1 were on treatment long enough to measure STAT3 levels at day 1 of cycle 2), and -31.1 (8.8) for cohort 2 (online supplemental figure 2).

An overall trend in decreased STAT3 expression was consistently observed, regardless of whether patients received danvatirsen alone or in combination with

durvalumab. Reduced STAT3 expression by danvatirsen was observed on day 1 of cycle 1 and the effect continued through the administration period.

### DISCUSSION

This is the first study to assess the safety, antitumour activity, PK and pharmacodynamics of danvatirsen monotherapy administered at a fixed dose, and of danvatirsen in combination with durvalumab in Japanese patients with advanced solid tumours. Danvatirsen monotherapy and danvatirsen plus durvalumab combination therapy were well tolerated by this study population. No new AEs for danvatirsen or durvalumab were detected. The combination was found to be safe for Japanese patients, which is consistent with findings reported in a phase 1b/2 study of patients with RM-HNSCC.<sup>17</sup> A phase 1/1b study of Asian/Japanese patients with HCC, in which danvatirsen was administered in per-body weight dosing via a 3-hour infusion, reported that the MTD of danvatirsen was 2 mg/kg dose (unpublished data). Of note, patients in the present study received danvatirsen via a 1-hour infusion and had an MTD of 200 mg (ie, corresponding to a 3 mg/kg dose). Furthermore, based on the previous phase 1/1b study results, we hypothesised that by excluding patients with HCC from the present study, we would remove confounding factors to evaluate study drug-related hepatotoxicity. Although hepatotoxicity was a DLT in this phase 1 study, patients had a lower frequency of hepatotoxicity compared with patients with HCC in the previous study. The difference in toxicity was attributed to the already compromised hepatic function of patients



**Figure 3** Percent change in target lesion size in treated patients. (A) Cohort 1 (danvatirsen monotherapy). (B) Cohort 2 (danvatirsen plus durvalumab combination therapy).



with HCC in the previous study (unpublished data). As the safety and tolerability of the danvatirsen 200 mg fixed dose were confirmed, we infer that fixed dosing does not impact safety.

The most common AEs possibly related to danvatirsen were platelet count decreased in cohort 1 and hepatic function abnormal, defined as ALT/AST/γGT increased, in cohort 2. Other danvatirsen studies have also reported reductions in platelet counts and elevated transaminases.<sup>9,10,17</sup> Although a few other antisense oligonucleotides have also been associated with thrombocytopenia,<sup>21–23</sup> the thrombocytopenia caused by danvatirsen treatment is considered to be associated with the on-target inhibition of STAT3, as a similar effect is observed with Janus kinase inhibitors.<sup>24</sup> Of note, these AEs were reversible when managed with dose interruptions and discontinuations as reported in a phase 1b/2 study of danvatirsen combined with durvalumab for advanced solid malignancies and recurrent metastatic HNSCC.<sup>17</sup>

Danvatirsen plasma concentrations declined in a biphasic manner, with a fast distribution phase and slow elimination phase. After multiple dosing of danvatirsen, there was no accumulation in plasma. No remarkable drug interactions were noted between danvatirsen (antisense oligonucleotide) and durvalumab (monoclonal antibody), likely because these drugs have different elimination routes. It should be noted that a population PK analysis of danvatirsen supporting flat dosing switch reported that race was not a significant covariate on the PK of danvatirsen.<sup>11</sup>

One patient developed antidanvatirsen antibodies. Of note, this patient's predose plasma concentrations of danvatirsen on day 1 of cycles 1, 2, 3 and 5 were higher than the overall geometric means in cohort 1. Although this patient presented with a grade 3 decrease in platelet count, no SAEs were reported. Thus, the presence of antidanvatirsen antibody did not seem to affect the patient's safety and PK.

In the present study, no cases of confirmed CR or PR were reported. At 12 weeks, none of the patients in cohort 1 achieved disease control, while three patients in cohort 2 did achieve disease control. A patient in cohort 2 with advanced oesophageal carcinoma and metastatic tumours in the liver and distant lymph nodes had an unconfirmed PR, presented the maximum decrease (over 49% reduction) in target lesion (hepatic metastasis) size from baseline and had a DoR of approximately 6 weeks. The patient died during study follow-up owing to disease progression. These findings indicate that while STAT3 inhibition was sustained in this patient (data not shown), the antitumour activity was not.

STAT3 knockdown by danvatirsen was observed regardless of whether patients received danvatirsen monotherapy or in combination with durvalumab. The reduction of STAT3 expression by danvatirsen was observed from day 1 of cycle 1, and the effect was maintained during the administration period in some cases. This finding implies that the sustained downregulation of STAT3 may

augment the antitumour activity of durvalumab via modulation of immune suppressive mechanisms in the tumour microenvironment. However, as none of the patients achieved disease control, either the STAT3 knockdown was insufficient or other immunosuppressive mechanisms interfered with the sustained effect of danvatirsen and prevented efficacy.

Although we have not explored specific resistance mechanisms that could make danvatirsen ineffective, many immunosuppressive mechanisms have been reported in the literature.<sup>25</sup> Possible resistance mechanisms to consider are cancer cell-intrinsic biology, the phenotype of the tumour microenvironment, and the biology of the patient,<sup>25</sup> which may act independently or be inter-related in a complex manner, causing drug resistance. Further research is needed to identify the mechanism of therapeutic resistance<sup>25</sup> to STAT3 inhibition.

The main limitation of this study was that the patient sample was small, which may affect the interpretation of the results. Additionally, patients had different types of solid tumours and were heavily pretreated. Finally, we did not evaluate progression-free survival in this study and could not further evaluate treatment efficacy in the patient who presented unconfirmed PR.

## CONCLUSIONS

Danvatirsen was well tolerated by Japanese patients with advanced solid tumours both as monotherapy and in combination with durvalumab. No new safety signals were raised for danvatirsen or durvalumab. The combination treatment with durvalumab did not result in relevant interactions nor did it largely affect the PK of danvatirsen. Antibodies to danvatirsen were only detected in one patient, but definitive conclusions cannot be drawn given the small sample size. Although there was no clinical benefit in patients receiving danvatirsen monotherapy, some benefit was observed in one patient receiving danvatirsen in combination with durvalumab. STAT3 knockdown was confirmed in this patient, consistent with a potential contribution of danvatirsen to the patient's clinical response. The combination of danvatirsen and durvalumab was tolerable. Inhibition of STAT3 in combination with inhibition of PD-L1 may be a complementary antitumour strategy.

### Author affiliations

<sup>1</sup>Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

<sup>2</sup>Research & Development, AstraZeneca K.K, Osaka, Japan

<sup>3</sup>Research & Development, AstraZeneca K.K, Tokyo, Japan

<sup>4</sup>Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan

**Present affiliations** The present affiliation of Naoto Yoshizuka is: Global Oncology R&D, Daiichi Sankyo, NJ, Basking Ridge, USA and Ko Sugibayashi is: Early Global Development, AstraZeneca, Cambridge, UK.

**Acknowledgements** The authors wish to thank Keyra Martinez Dunn, MD, of Edanz, Japan, for providing medical writing support, which was funded by



AstraZeneca K.K., Osaka, Japan, through EMC K.K., Japan, in accordance with Good Publication Practice guidelines (<http://www.ismpp.org/gpp3>).

**Contributors** TN and YK participated in the data acquisition and the interpretation of the data. TF and KM participated in the interpretation of the data. NY participated in the design of the study and the interpretation of the data. KS participated in the conception and design of the study and the interpretation of the data. TF accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. All authors contributed to drafting, critically reviewing and final approval of the manuscript and are accountable for the accuracy and integrity of the data being reported.

**Funding** This work was supported by AstraZeneca K.K., Osaka, Japan.

**Competing interests** TN has received grants from AstraZeneca K.K., during the conduct of the study; grants from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., and Sumitomo Dainippon Pharma Co., Ltd., outside the submitted work. TF is an employee of, and reports stock ownership in, AstraZeneca K.K. NY is an employee of AstraZeneca K.K. KS is an employee of, and reports stock ownership in, AstraZeneca K.K. YK has received grants and honoraria from Taiho Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd.; honoraria from Bayer Yakuhin, Ltd., Sanofi K.K., Eli Lilly Japan K.K., and Bristol-Myers Squibb K.K.; and grants from Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Amgen K.K., Chugai Pharmaceutical Co., Ltd., AbbVie GK, and GlaxoSmithKline K.K., outside the submitted work.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by National Cancer Center Hospital IRB: K0682 and National Hospital Organization Shikoku Cancer Center IRB: 2017-31. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at <https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure>.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Tomohiro Nishina <http://orcid.org/0000-0002-4073-3757>  
Tomoko Fujita <http://orcid.org/0000-0002-6629-6380>  
Naoto Yoshizuka <http://orcid.org/0000-0002-2798-2564>  
Ko Sugibayashi <http://orcid.org/0000-0003-0285-8054>  
Kosho Murayama <http://orcid.org/0000-0003-3301-9966>  
Yasutoshi Kuboki <http://orcid.org/0000-0003-3675-953X>


## REFERENCES

- 1 Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. *Sci Rep* 2015;5:17663.


- 2 Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol* 2007;7:41–51.
- 3 Yang L, Lin S, Xu L, et al. Novel activators and small-molecule inhibitors of STAT3 in cancer. *Cytokine Growth Factor Rev* 2019;49:10–22.
- 4 Cao H-H, Chu J-H, Kwan H-Y, et al. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. *Sci Rep* 2016;6:21731.
- 5 Cao H-H, Liu D-Y, Lai Y-C, et al. Inhibition of the STAT3 signaling pathway contributes to the anti-melanoma activities of shikonin. *Front Pharmacol* 2020;11:748.
- 6 Furqan M, Akinleye A, Mukhi N, et al. STAT inhibitors for cancer therapy. *J Hematol Oncol* 2013;6:90.
- 7 Seth PP, Vasquez G, Allerson CA, et al. Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues. *J Org Chem* 2010;75:1569–81.
- 8 Proia TA, Singh M, Woessner R, et al. STAT3 antisense oligonucleotide remodels the suppressive tumor microenvironment to enhance immune activation in combination with anti-PD-L1. *Clin Cancer Res* 2020;26:6335–49.
- 9 Hong D, Kurzrock R, Kim Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. *Sci Transl Med* 2015;7:314ra185.
- 10 Reilly MJ, McCoon P, Cook C, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. *J Immunother Cancer* 2018;6:119.
- 11 Xu H, Tong X, Mugundu G, et al. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. *J Pharmacokinet Pharmacodyn* 2019;46:65–74.
- 12 Syed YY. Durvalumab: first global approval. *Drugs* 2017;77:1369–76.
- 13 Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med* 2018;379:2342–50.
- 14 Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet* 2019;394:1929–39.
- 15 Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Ann Oncol* 2019;30:1279–88.
- 16 Fujiwara Y, Iguchi H, Yamamoto N, et al. Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. *Cancer Sci* 2019;110:1715–23.
- 17 Cohen EEW, Harrington KJ, Hong DS, et al. A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): updated results. *Ann Oncol* 2018;29:viii372.
- 18 Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. *Eur J Cancer* 2019;107:142–52.
- 19 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.
- 20 Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009;15:7412–20.
- 21 Jason TLH, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. *Toxicol Appl Pharmacol* 2004;201:66–83.
- 22 Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. *Toxicol Pathol* 2015;43:78–89.
- 23 Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. *Drug Discov Today* 2017;22:823–33.
- 24 Sonbol MB, Firwana B, Zarzour A, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. *Ther Adv Hematol* 2013;4:15–35.
- 25 Aldea M, Andre F, Marabelle A, et al. Overcoming resistance to tumor-targeted and immune-targeted therapies. *Cancer Discov* 2021;11:874–99.

**Supplementary materials**

**Supplementary Figure 1.** Geometric mean ( $\pm$ standard deviation) plasma concentrations (ng/mL) of danvatirsen versus time (pharmacokinetic analysis set). (A) In lead-in phase, Day -7 of Cohort 1 and Cohort 2. (B) In lead-in phase, Day -7 and Cycle 2, Day 1 of Cohort 1. (C) In lead-in phase, Day -7 and Cycle 2, Day 1 of Cohort 2.



**Supplementary Figure 2.** Pharmacodynamics of danvatirsen (% change from baseline of STAT3) by treatment cycle (pharmacodynamics analysis set)



**Supplementary Table 1.** Incidence of adverse events overall and by system organ class and preferred term

	Danvatirsen monotherapy (Cohort 1) N=5	Danvatirsen plus durvalumab (Cohort 2) N=6
AE category	Number of patients <sup>a</sup> (%)	
Any AE	4 (80.0)	6 (100.0)
AE causally related to treatment <sup>b</sup>	3 (60.0)	6 (100.0)
AE causally related to danvatirsen only <sup>b</sup>	3 (60.0)	5 (83.3)
AE causally related to durvalumab only <sup>b</sup>	NA	0
AE causally related to danvatirsen and durvalumab <sup>b</sup>	NA	2 (33.3)
AE of CTCAE Grade ≥3	3 (60.0)	6 (100.0)
AE of CTCAE Grade ≥3, causally related to treatment <sup>b</sup>	0	5 (83.3)
AE of CTCAE Grade ≥3, causally related to danvatirsen only <sup>b</sup>	0	5 (83.3)
AE of CTCAE Grade ≥3, causally related to durvalumab only <sup>b</sup>	NA	0
AE of CTCAE Grade ≥3, causally related to danvatirsen and durvalumab <sup>b</sup>	NA	0
AE with outcome = death	0	0
AE with outcome = death, causally related to treatment <sup>b</sup>	0	0
SAE (including events with outcome = death)	1 (20.0)	0
SAE (including events with outcome = death), causally related to treatment <sup>b</sup>	0	0
SAE causing discontinuation of danvatirsen	0	0
SAE causing discontinuation of danvatirsen, causally related to treatment <sup>b</sup>	0	0
AE leading to discontinuation of danvatirsen	0	1 (16.7)
AE leading to dose modification of danvatirsen	1 (20.0)	4 (66.7)
AE leading to dose reduction of danvatirsen	0	3 (50.0)
AE leading to dose interruption of danvatirsen	1 (20.0)	1 (16.7)
Other significant AEs <sup>c</sup>	0	0



System organ class / Preferred term		
Hepatobiliary disorders	0	3 (50.0)
Hepatic function abnormal	0	3 (50.0)
General disorders and administration site conditions	1 (20.0)	4 (66.7)
Malaise	1 (20.0)	2 (33.3)
Pyrexia	1 (20.0)	1 (16.7)
Fatigue	0	1 (16.7)
Investigations	4 (80.0)	4 (66.7)
Platelet count decreased	3 (60.0)	2 (33.3)
Gamma-glutamyltransferase increased	1 (20.0)	2 (33.3)
Neutrophil count decreased	0	2 (33.3)
Alanine aminotransferase increased	1 (20.0)	1 (16.7)
Aspartate aminotransferase increased	1 (20.0)	1 (16.7)
Blood bilirubin increased	1 (20.0)	0
Blood lactate dehydrogenase increased	0	1 (16.7)
Weight increased	1 (20.0)	0
Blood alkaline phosphatase increased	0	1 (16.7)

<sup>a</sup>Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

<sup>b</sup>As assessed by the Investigator, and derived from individual causality assessments for combination studies.

<sup>c</sup>Significant AEs, other than SAEs and those AEs leading to discontinuation of the study.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; NA, not applicable; SAE, serious adverse event

**Supplementary Table 2.** Summary of danvatirsen pharmacokinetic parameters after a single and multiple intravenous infusions in Cohorts 1 and 2

		Danvatirsen monotherapy (Cohort 1) N=5	Danvatirsen plus durvalumab (Cohort 2) N=6
<b>Single intravenous infusion of danvatirsen 200 mg over 1 hour on Day -7 of the lead-in period</b>			
C <sub>max</sub> , ng/mL	Geometric mean (CV%)	36570 (13.28)	35960 (24.18)
t <sub>max</sub> , h	Median (range)	1.00 (0.97–1.08)	0.985 (0.95–1.05)
AUC <sub>(0-6)</sub> , ng·h/mL	Geometric mean (CV%)	73930 (7.92)	77270 (31.75)
AUC <sub>(0-48)</sub> , ng·h/mL	Geometric mean (CV%)	90110 (8.179)	95940 (32.8)
AUC <sub>(0-t)</sub> , ng·h/mL	Geometric mean (CV%)	90120 (8.201)	95930 (32.8)
AUC <sub>(0-∞)</sub> , ng·h/mL	Geometric mean (CV%)	90190 (8.189)	96010 (32.78)
CL, L/h	Mean (SD)	2.223 (0.1798)	2.176 (0.7228)
V <sub>z</sub> , L	Mean (SD)	16.27 (1.199)	15.76 (5.885)
MRT, h	Mean (SD)	3.604 (0.4443)	3.705 (0.2352)
<b>Once weekly intravenous infusion at danvatirsen 200 mg over 1 hour on Cycle 2 Day 1</b>			
C <sub>ss max</sub> , ng/mL	Geometric mean (range)	34470 (33700–35200)	34470 (18400–36900)
t <sub>ss max</sub> , h	Median (range)	1.05 (1.03–1.07)	1.00 (0.95–1.05)
AUC <sub>(0-6)</sub> , ng·h/mL	Geometric mean (range)	69850 (67100–72700)	51090 (37100–74900)
AUC <sub>(0-t)</sub> , ng·h/mL	Geometric mean (range)	69900 (67300–72600)	50830 (37000–74100)
C <sub>trough</sub> , ng/mL	Geometric mean (range)	28.02 (20.4–38.5)	27.92 (18.1–46.2)
R <sub>AC</sub>	Mean (range)	0.941 (0.887–0.995)	0.7402 (0.582–0.947)

AUC, area under the plasma concentration-time curve; AUC<sub>(0-6)</sub>, AUC from zero to 6 hours; AUC<sub>(0-48)</sub>, AUC from zero to 48 hours; AUC<sub>(0-t)</sub>, AUC from zero to 6 hours; AUC<sub>(0-∞)</sub>, AUC from zero to infinity; CL, plasma clearance; C<sub>max</sub>, maximum plasma concentration; C<sub>ss max</sub>, maximum plasma concentration at steady state; CV, coefficient of variation; max, maximum; min, minimum; MRT, mean residence time; R<sub>AC</sub>, extent of accumulation on multiple dosing; SD, standard deviation; t<sub>max</sub>, time to maximum plasma concentration; t<sub>ss max</sub>, time to maximum plasma concentration at steady state; V<sub>z</sub>, volume of distribution

**Supplementary Table 3.** Summary of antitumor activity results

		<b>Danvatirsen monotherapy (Cohort 1) N=5</b>	<b>Danvatirsen plus durvalumab (Cohort 2) N=6</b>
<b>Best objective response</b>			
Response	Total	0	0
	Complete response <sup>a</sup>	0	0
	Partial response <sup>a</sup>	0	0
Non-response	Total	5 (100.0)	6 (100.0)
	Stable disease ≥6 weeks	0	5 (83.3)
	Progression	5 (100.0)	1 (16.7)
	RECIST progression	4 (80.0)	1 (16.7)
	Death	1 (20.0)	0
	Not evaluable	0	0
<b>Disease control rate</b>			
Disease control at 12 weeks <sup>b</sup>	Yes	0	3 (50.0)
	No	5 (100.0)	3 (50.0)

<sup>a</sup> Response required confirmation.<sup>b</sup> Disease control = confirmed complete response + confirmed partial response + stable disease at or after 12 weeks.

RECIST, Response Evaluation Criteria in Solid Tumors

## Supplementary information

Dose-limiting toxicity (DLT) was defined as any  $\geq$ Grade 3 adverse event per the National Cancer Institute Common Terminology Criteria for Adverse Events, with the following exceptions:

- Increase in transaminase level (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) was considered a DLT if:
  - AST and/or ALT increased to  $>15\times$  the upper limit of normal [ULN] at any time;
  - AST and/or ALT increased to  $>10\times$  to  $15\times$ ULN over 14 consecutive days; and/or
  - AST and/or ALT increased to  $>5\times$ ULN, and one or more of the following conditions was met and not explained by other causes:
    1. Total bilirubin increased to  $>2\times$ ULN
    2. New appearance of eosinophilia ( $>5\%$ )
    3. Clinical signs of functional liver impairment
- Nausea, vomiting, and diarrhea were considered DLTs only if assessed as  $\geq$ Grade 3 after optimal prophylactic or treatment measures have been prescribed.
- Fatigue was not considered a DLT.
- Neutropenia was considered a DLT only in the case of:
  - Grade 3 febrile neutropenia (i.e., absolute neutrophil count [ANC]  $<1,000/\text{mm}^3$ ) with a single temperature reading of  $>38.3^\circ\text{C}$  or a sustained temperature of  $\geq 38^\circ\text{C}$  for more than 1 hour);
  - Grade 4 febrile neutropenia (i.e., ANC  $<1,000/\text{mm}^3$ ) with life-threatening consequences indicating urgent intervention;
  - $\geq$ Grade 3 (i.e., ANC  $<1,000/\text{mm}^3$ ) associated with an infection that was clinically severe, associated with sepsis, or requiring hospitalization. Grade 3 non-febrile




neutropenia with clinically minor infection (as judged by the investigator) was not considered a DLT; or


- Grade 4 (i.e., ANC  $<500/\text{mm}^3$ ) sustained for more than 5 days.
- Thrombocytopenia was considered a DLT only in the case of:
  - $\geq$ Grade 3 thrombocytopenia (i.e., platelet count  $<50,000/\text{mm}^3$ ) associated with bleeding; or
  - Grade 4 thrombocytopenia (i.e., platelet count  $<25,000/\text{mm}^3$ ).
- Any toxicity judged by the Investigator to be drug that required study treatment to be interrupted for more than 10 consecutive days was considered a DLT.
- Any other Grade 3 or Grade 4 laboratory evaluations that were asymptomatic but assessed by the Investigator as clinically significant were considered DLTs.

**Supplementary materials**

**Supplementary Figure 1.** Geometric mean ( $\pm$ standard deviation) plasma concentrations (ng/mL) of danvatirsen versus time (pharmacokinetic analysis set). (A) In lead-in phase, Day -7 of Cohort 1 and Cohort 2. (B) In lead-in phase, Day -7 and Cycle 2, Day 1 of Cohort 1. (C) In lead-in phase, Day -7 and Cycle 2, Day 1 of Cohort 2.



**Supplementary Figure 2.** Pharmacodynamics of danvatirsen (% change from baseline of STAT3) by treatment cycle (pharmacodynamics analysis set)



**Supplementary Table 1.** Incidence of adverse events overall and by system organ class and preferred term

	Danvatirsen monotherapy (Cohort 1) N=5	Danvatirsen plus durvalumab (Cohort 2) N=6
AE category	Number of patients <sup>a</sup> (%)	
Any AE	4 (80.0)	6 (100.0)
AE causally related to treatment <sup>b</sup>	3 (60.0)	6 (100.0)
AE causally related to danvatirsen only <sup>b</sup>	3 (60.0)	5 (83.3)
AE causally related to durvalumab only <sup>b</sup>	NA	0
AE causally related to danvatirsen and durvalumab <sup>b</sup>	NA	2 (33.3)
AE of CTCAE Grade ≥3	3 (60.0)	6 (100.0)
AE of CTCAE Grade ≥3, causally related to treatment <sup>b</sup>	0	5 (83.3)
AE of CTCAE Grade ≥3, causally related to danvatirsen only <sup>b</sup>	0	5 (83.3)
AE of CTCAE Grade ≥3, causally related to durvalumab only <sup>b</sup>	NA	0
AE of CTCAE Grade ≥3, causally related to danvatirsen and durvalumab <sup>b</sup>	NA	0
AE with outcome = death	0	0
AE with outcome = death, causally related to treatment <sup>b</sup>	0	0
SAE (including events with outcome = death)	1 (20.0)	0
SAE (including events with outcome = death), causally related to treatment <sup>b</sup>	0	0
SAE causing discontinuation of danvatirsen	0	0
SAE causing discontinuation of danvatirsen, causally related to treatment <sup>b</sup>	0	0
AE leading to discontinuation of danvatirsen	0	1 (16.7)
AE leading to dose modification of danvatirsen	1 (20.0)	4 (66.7)
AE leading to dose reduction of danvatirsen	0	3 (50.0)
AE leading to dose interruption of danvatirsen	1 (20.0)	1 (16.7)
Other significant AEs <sup>c</sup>	0	0



System organ class / Preferred term		
Hepatobiliary disorders	0	3 (50.0)
Hepatic function abnormal	0	3 (50.0)
General disorders and administration site conditions	1 (20.0)	4 (66.7)
Malaise	1 (20.0)	2 (33.3)
Pyrexia	1 (20.0)	1 (16.7)
Fatigue	0	1 (16.7)
Investigations	4 (80.0)	4 (66.7)
Platelet count decreased	3 (60.0)	2 (33.3)
Gamma-glutamyltransferase increased	1 (20.0)	2 (33.3)
Neutrophil count decreased	0	2 (33.3)
Alanine aminotransferase increased	1 (20.0)	1 (16.7)
Aspartate aminotransferase increased	1 (20.0)	1 (16.7)
Blood bilirubin increased	1 (20.0)	0
Blood lactate dehydrogenase increased	0	1 (16.7)
Weight increased	1 (20.0)	0
Blood alkaline phosphatase increased	0	1 (16.7)

<sup>a</sup>Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

<sup>b</sup>As assessed by the Investigator, and derived from individual causality assessments for combination studies.

<sup>c</sup>Significant AEs, other than SAEs and those AEs leading to discontinuation of the study.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; NA, not applicable; SAE, serious adverse event

**Supplementary Table 2.** Summary of danvatirsen pharmacokinetic parameters after a single and multiple intravenous infusions in Cohorts 1 and 2

		Danvatirsen monotherapy (Cohort 1) N=5	Danvatirsen plus durvalumab (Cohort 2) N=6
<b>Single intravenous infusion of danvatirsen 200 mg over 1 hour on Day -7 of the lead-in period</b>			
C <sub>max</sub> , ng/mL	Geometric mean (CV%)	36570 (13.28)	35960 (24.18)
t <sub>max</sub> , h	Median (range)	1.00 (0.97–1.08)	0.985 (0.95–1.05)
AUC <sub>(0-6)</sub> , ng·h/mL	Geometric mean (CV%)	73930 (7.92)	77270 (31.75)
AUC <sub>(0-48)</sub> , ng·h/mL	Geometric mean (CV%)	90110 (8.179)	95940 (32.8)
AUC <sub>(0-t)</sub> , ng·h/mL	Geometric mean (CV%)	90120 (8.201)	95930 (32.8)
AUC <sub>(0-∞)</sub> , ng·h/mL	Geometric mean (CV%)	90190 (8.189)	96010 (32.78)
CL, L/h	Mean (SD)	2.223 (0.1798)	2.176 (0.7228)
V <sub>z</sub> , L	Mean (SD)	16.27 (1.199)	15.76 (5.885)
MRT, h	Mean (SD)	3.604 (0.4443)	3.705 (0.2352)
<b>Once weekly intravenous infusion at danvatirsen 200 mg over 1 hour on Cycle 2 Day 1</b>			
C <sub>ss max</sub> , ng/mL	Geometric mean (range)	34470 (33700–35200)	34470 (18400–36900)
t <sub>ss max</sub> , h	Median (range)	1.05 (1.03–1.07)	1.00 (0.95–1.05)
AUC <sub>(0-6)</sub> , ng·h/mL	Geometric mean (range)	69850 (67100–72700)	51090 (37100–74900)
AUC <sub>(0-t)</sub> , ng·h/mL	Geometric mean (range)	69900 (67300–72600)	50830 (37000–74100)
C <sub>trough</sub> , ng/mL	Geometric mean (range)	28.02 (20.4–38.5)	27.92 (18.1–46.2)
R <sub>AC</sub>	Mean (range)	0.941 (0.887–0.995)	0.7402 (0.582–0.947)

AUC, area under the plasma concentration-time curve; AUC<sub>(0-6)</sub>, AUC from zero to 6 hours; AUC<sub>(0-48)</sub>, AUC from zero to 48 hours; AUC<sub>(0-6)</sub>, AUC from zero to 6 hours; AUC<sub>(0-t)</sub>, AUC from zero to the time of the last measurable concentration; AUC<sub>(0-∞)</sub>, AUC from zero to infinity; CL, plasma clearance; C<sub>max</sub>, maximum plasma concentration; C<sub>ss max</sub>, maximum plasma concentration at steady state; CV, coefficient of variation; max, maximum; min, minimum; MRT, mean residence time; R<sub>AC</sub>, extent of accumulation on multiple dosing; SD, standard deviation; t<sub>max</sub>, time to maximum plasma concentration; t<sub>ss max</sub>, time to maximum plasma concentration at steady state; V<sub>z</sub>, volume of distribution

**Supplementary Table 3.** Summary of antitumor activity results

		Danvatirsen monotherapy (Cohort 1) N=5	Danvatirsen plus durvalumab (Cohort 2) N=6
<b>Best objective response</b>			
Response	Total	0	0
	Complete response <sup>a</sup>	0	0
	Partial response <sup>a</sup>	0	0
Non-response	Total	5 (100.0)	6 (100.0)
	Stable disease ≥6 weeks	0	5 (83.3)
	Progression	5 (100.0)	1 (16.7)
	RECIST progression	4 (80.0)	1 (16.7)
	Death	1 (20.0)	0
	Not evaluable	0	0
<b>Disease control rate</b>			
Disease control at 12 weeks <sup>b</sup>	Yes	0	3 (50.0)
	No	5 (100.0)	3 (50.0)

<sup>a</sup> Response required confirmation.<sup>b</sup> Disease control = confirmed complete response + confirmed partial response + stable disease at or after 12 weeks.

RECIST, Response Evaluation Criteria in Solid Tumors

## Supplementary information

Dose-limiting toxicity (DLT) was defined as any  $\geq$ Grade 3 adverse event per the National Cancer Institute Common Terminology Criteria for Adverse Events, with the following exceptions:

- Increase in transaminase level (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) was considered a DLT if:
  - AST and/or ALT increased to  $>15\times$  the upper limit of normal [ULN] at any time;
  - AST and/or ALT increased to  $>10\times$  to  $15\times$ ULN over 14 consecutive days; and/or
  - AST and/or ALT increased to  $>5\times$ ULN, and one or more of the following conditions was met and not explained by other causes:
    1. Total bilirubin increased to  $>2\times$ ULN
    2. New appearance of eosinophilia ( $>5\%$ )
    3. Clinical signs of functional liver impairment
- Nausea, vomiting, and diarrhea were considered DLTs only if assessed as  $\geq$ Grade 3 after optimal prophylactic or treatment measures have been prescribed.
- Fatigue was not considered a DLT.
- Neutropenia was considered a DLT only in the case of:
  - Grade 3 febrile neutropenia (i.e., absolute neutrophil count [ANC]  $<1,000/\text{mm}^3$ ) with a single temperature reading of  $>38.3^\circ\text{C}$  or a sustained temperature of  $\geq 38^\circ\text{C}$  for more than 1 hour);
  - Grade 4 febrile neutropenia (i.e., ANC  $<1,000/\text{mm}^3$ ) with life-threatening consequences indicating urgent intervention;
  - $\geq$ Grade 3 (i.e., ANC  $<1,000/\text{mm}^3$ ) associated with an infection that was clinically severe, associated with sepsis, or requiring hospitalization. Grade 3 non-febrile

neutropenia with clinically minor infection (as judged by the investigator) was not considered a DLT; or

- Grade 4 (i.e., ANC  $<500/\text{mm}^3$ ) sustained for more than 5 days.
- Thrombocytopenia was considered a DLT only in the case of:
  - $\geq$ Grade 3 thrombocytopenia (i.e., platelet count  $<50,000/\text{mm}^3$ ) associated with bleeding; or
  - Grade 4 thrombocytopenia (i.e., platelet count  $<25,000/\text{mm}^3$ ).
- Any toxicity judged by the Investigator to be drug that required study treatment to be interrupted for more than 10 consecutive days was considered a DLT.
- Any other Grade 3 or Grade 4 laboratory evaluations that were asymptomatic but assessed by the Investigator as clinically significant were considered DLTs.